Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chiesi Farmaceutici SpA - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Chiesi Farmaceutici SpA - Product Pipeline Review - 2016', provides an overview of the Chiesi Farmaceutici SpA's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Chiesi Farmaceutici SpA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Chiesi Farmaceutici SpA - The report provides overview of Chiesi Farmaceutici SpA including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Chiesi Farmaceutici SpA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Chiesi Farmaceutici SpA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Chiesi Farmaceutici SpA's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chiesi Farmaceutici SpA - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chiesi Farmaceutici SpA's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Chiesi Farmaceutici SpA Snapshot 6 Chiesi Farmaceutici SpA Overview 6 Key Facts 6 Chiesi Farmaceutici SpA - Research and Development Overview 7 Key Therapeutic Areas 7 Chiesi Farmaceutici SpA - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Chiesi Farmaceutici SpA - Pipeline Products Glance 17 Chiesi Farmaceutici SpA - Late Stage Pipeline Products 17 Phase III Products/Combination Treatment Modalities 17 Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Chiesi Farmaceutici SpA - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products 21 Unknown Products/Combination Treatment Modalities 21 Chiesi Farmaceutici SpA - Drug Profiles 22 (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 budesonide - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CHF-5633 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 CHF-6001 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 CHF-6297 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CPD-15 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Drugs for Bronchopulmonary Dysplasia - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 glycopyrrolate - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 melatonin - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 meropenem - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Recombinant Enzymes for Rare Diseases - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Recombinant Protein for Neonatal Respiratory Distress Syndrome - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 TRP-601 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 velmanase alfa - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Chiesi Farmaceutici SpA - Pipeline Analysis 45 Chiesi Farmaceutici SpA - Pipeline Products by Target 45 Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration 47 Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type 48 Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action 49 Chiesi Farmaceutici SpA - Dormant Projects 51 Chiesi Farmaceutici SpA - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 53 beclomethasone dipropionate SR 53 carmoterol 53 indantadol 53 Porphozym 53 Chiesi Farmaceutici SpA - Company Statement 54 Chiesi Farmaceutici SpA - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 57 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables Chiesi Farmaceutici SpA, Key Facts 6 Chiesi Farmaceutici SpA - Pipeline by Indication, 2016 9 Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2016 10 Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2016 11 Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2016 12 Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2016 13 Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2016 14 Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2016 15 Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2016 16 Chiesi Farmaceutici SpA - Phase III, 2016 17 Chiesi Farmaceutici SpA - Phase II, 2016 18 Chiesi Farmaceutici SpA - Phase I, 2016 19 Chiesi Farmaceutici SpA - Preclinical, 2016 20 Chiesi Farmaceutici SpA - Unknown, 2016 21 Chiesi Farmaceutici SpA - Pipeline by Target, 2016 46 Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2016 47 Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2016 48 Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2016 50 Chiesi Farmaceutici SpA - Dormant Developmental Projects,2016 51 Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2016 52 Chiesi Farmaceutici SpA, Subsidiaries 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
